Literature DB >> 2901121

Remoxipride--a new potential antipsychotic drug. Pharmacological effects and pharmacokinetics following repeated oral administration in male volunteers.

L Farde1, M Grind, M I Nilsson, S Ogenstad, G Sedvall.   

Abstract

Remoxipride, a new potential antipsychotic drug, was administered over 4 days at two dose levels, 70 and 140 mg t.i.d., to eight healthy male volunteers. Pharmacokinetics, safety, tolerability, and effect on plasma prolactin levels were evaluated. Remoxipride exhibited essentially linear pharmacokinetics. Only minor deviations in biochemical and physiological safety parameters were found. The drug was well tolerated by all subjects at the 70 mg dose level. At 140 mg akathisia appeared in seven subjects. The drug induced a rapid and transient increase in plasma prolactin concentrations at both dose levels after single doses. During steady state, a significant reduction in the prolactin response was observed as compared to after the first dose.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901121     DOI: 10.1007/bf00174501

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  16 in total

1.  The SHP test--an aid in the detection and measurement of depression.

Authors:  R E PECK
Journal:  AMA Arch Gen Psychiatry       Date:  1959-07

2.  Akathisia: the syndrome of motor restlessness.

Authors:  J R HODGE
Journal:  Am J Psychiatry       Date:  1959-10       Impact factor: 18.112

3.  Motor disorders induced by neuroleptics: a proposed new classification.

Authors:  G E Crane; E R Naranjo
Journal:  Arch Gen Psychiatry       Date:  1971-02

4.  Potential neuroleptic agents. 2. Synthesis and dopamine blocking activity of some new 2,6-dimethoxybenzamide derivatives.

Authors:  L Florvall; M L Persson; S O Ogren
Journal:  Acta Pharm Suec       Date:  1983

5.  Akathisia variants and tardive dyskinesia.

Authors:  T R Barnes; W M Braude
Journal:  Arch Gen Psychiatry       Date:  1985-09

6.  Prolonged adverse effects of haloperidol in normal subjects.

Authors:  B G Anderson; D Reker; T B Cooper
Journal:  N Engl J Med       Date:  1981-09-10       Impact factor: 91.245

7.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.

Authors:  L Farde; H Hall; E Ehrin; G Sedvall
Journal:  Science       Date:  1986-01-17       Impact factor: 47.728

8.  Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.

Authors:  S O Ogren; H Hall; C Köhler; O Magnusson; L O Lindbom; K Angeby; L Florvall
Journal:  Eur J Pharmacol       Date:  1984-07-20       Impact factor: 4.432

9.  Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions.

Authors:  W M Braude; T R Barnes; S M Gore
Journal:  Br J Psychiatry       Date:  1983-08       Impact factor: 9.319

10.  An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET.

Authors:  L Farde; F A Wiesel; P Jansson; G Uppfeldt; A Wahlen; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more
  13 in total

Review 1.  Biomarkers for the effects of antipsychotic drugs in healthy volunteers.

Authors:  S J de Visser; J van der Post; M S Pieters; A F Cohen; J M van Gerven
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

2.  Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia.

Authors:  E Widerlöv; U Andersson; C von Bahr; M I Nilsson
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Effects of remoxipride on measures of psychological performance in healthy volunteers.

Authors:  D Fagan; D B Scott; M Mitchell; B Tiplady
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Remoxipride: pharmacokinetics and effect on plasma prolactin.

Authors:  G Movin-Osswald; M Hammarlund-Udenaes
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

5.  Influence of the dosing interval on prolactin release after remoxipride.

Authors:  G Movin-Osswald; M Hammarlund-Udenaes; C Von Bahr; P Eneroth; K Walton-Bowen
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

6.  Interaction study between remoxipride and biperiden.

Authors:  W Yisak; L Farde; C von Bahr; L B Nilsson; G Fredriksson; S Ogenstad
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans--a PET study with [11C]SCH 23390 and [11C]raclopride.

Authors:  L Farde
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 8.  Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia.

Authors:  A N Wadworth; R C Heel
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

9.  In vivo validation of the release rate and palatability of remoxipride-modified release suspension.

Authors:  R Sjöqvist; C Graffner; I Ekman; W Sinclair; J P Woods
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

10.  Steady-state pharmacokinetics of controlled release and immediate release formulations of remoxipride in patients with chronic schizophrenia.

Authors:  D Tench; S D Soni; T Ashwood; G Movin
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.